AMENDMENTS TO EXECUTIVE EMPLOYMENT AGREEMENTS
Exhibit 10.1
AMENDMENTS TO EXECUTIVE EMPLOYMENT AGREEMENTS
On April 28, 2014, ARIAD Pharmaceuticals, Inc. (the “Company”) extended the term of the employment agreement of each of the following executive officers, as follows:
| Term of Agreement Extended | ||||
| Name and Title | From | To | ||
| David L. Berstein, Esq. Senior Vice President, General Counsel and Chief Intellectual Property Counsel, and Secretary | December 31, 2014 | December 31, 2016 | ||
| Daniel M. Bollag, Ph.D Senior Vice President, Regulatory Affairs and Quality | December 31, 2014 | December 31, 2016 | ||
| Maria E. Cantor Senior Vice President, Corporate Affairs and Human Resources | June 30, 2015 | December 31, 2016 | ||
| Timothy P. Clackson, Ph.D. President of Research and Development and Chief Scientific Officer | June 30, 2015 | December 31, 2016 | ||
| Martin J. Duvall Executive Vice President and Chief Commercial Officer | December 31, 2014 | December 31, 2016 | ||
| Edward M. Fitzgerald Executive Vice President, Chief Financial Officer and Treasurer | June 30, 2015 | December 31, 2016 | ||
| Frank G. Haluska, M.D., Ph.D. Senior Vice President, Clinical Research and Development and Chief Medical Officer | December 31, 2014 | December 31, 2016 | ||
The term of employment for each officer is thereafter subject to automatic renewal for successive one-year terms absent notice to the contrary by either party, as provided in their employment agreements.
The terms of employment for each of Harvey J. Berger, M.D., Chairman and Chief Executive Officer, and Hugh M. Cole, Senior Vice President, Chief Business Officer, remain December 31, 2016, subject to automatic renewal as provided in their employment agreements.
